Does PALBOCICLIB Cause Poor venous access? 19 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Poor venous access have been filed in association with PALBOCICLIB (Ibrance). This represents 0.0% of all adverse event reports for PALBOCICLIB.
19
Reports of Poor venous access with PALBOCICLIB
0.0%
of all PALBOCICLIB reports
1
Deaths
12
Hospitalizations
How Dangerous Is Poor venous access From PALBOCICLIB?
Of the 19 reports, 1 (5.3%) resulted in death, 12 (63.2%) required hospitalization, and 1 (5.3%) were considered life-threatening.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 19 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Poor venous access?
VEDOLIZUMAB (1,043)
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
Which PALBOCICLIB Alternatives Have Lower Poor venous access Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID